Compare BBY & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBY | ALNY |
|---|---|---|
| Founded | 1966 | 2002 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2B | 21.6B |
| IPO Year | 1994 | 2004 |
| Metric | BBY | ALNY |
|---|---|---|
| Price | $101.23 | $156.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 25 | 30 |
| Target Price | $87.85 | ★ $302.48 |
| AVG Volume (30 Days) | ★ 2.8M | 2.5M |
| Earning Date | 11-24-2026 | 10-29-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | 17.76 | ★ 206.88 |
| EPS | 2.79 | ★ 18.42 |
| Revenue | ★ $41,691,000,000.00 | $1,037,418,000.00 |
| Revenue This Year | $2.34 | $46.44 |
| Revenue Next Year | $1.67 | $20.78 |
| P/E Ratio | $36.33 | ★ $8.74 |
| Revenue Growth | 0.39 | ★ 22.88 |
| 52 Week Low | $55.10 | $156.00 |
| 52 Week High | $101.49 | $479.79 |
| Indicator | BBY | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 60.52 | 21.96 |
| Support Level | $59.52 | N/A |
| Resistance Level | N/A | $237.47 |
| Average True Range (ATR) | 3.54 | 10.24 |
| MACD | 0.27 | -6.26 |
| Stochastic Oscillator | 79.44 | 2.62 |
Best Buy Co Inc is a pure-play consumer electronics retailer in the USA. It has two reportable segments: Domestic and International. The Domestic and International segments have offerings in six revenue categories. Computing and Mobile Phones, Consumer Electronics, Appliances, Entertainment, Services, and Other. The company has approximately 1,068 stores throughout its Domestic and International segments. It also have vendor store-within-a-store concepts to allow closer vendor partnerships and a higher quality customer experience. The company generates majority of its revenue from the Domestic segment.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.